Navigation Links
Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC's Regulatory Announcement

ROSEAU, Commonwealth of Dominica, June 19 /PRNewswire/ -- Neuftec Limited, the proprietor of the original nano-particulate cerium oxide fuel catalyst technology, which recently issued a claim against Oxonica Energy Limited, a wholly owned subsidiary of Oxonica PLC, for infringement of its European Patent in the High Court of Justice, has commented on a fundamental inaccuracy in Oxonica's AGM Statement issued by Dr Matthews (CEO) on 19 June 2008.

Dr Kevin Matthews stated in the recent Regulatory Announcement that:

"In 2007 Neuftec acknowledged that Envirox as supplied by Nyacol, Oxonica's strategic partner, does not fall within the claims of their granted patent, EP(UK) 1299 508."

In May 2007, Oxonica provided Neuftec with a confidential statement containing what it claimed to be the chemical composition of Envirox sold to Petrol Ofisi. Based on that information alone, Neuftec confirmed in June 2007 that the second source product supplied to Petrol Ofisi did not come within the scope of claims of Neuftec's patent. Neuftec has never acknowledged that Envirox products sold to customers other than Petrol Ofisi did not infringe Neuftec's European patent.

Neuftec has obtained samples of Oxonica's Envirox formulation produced by Nyacol and conducted a preliminary analysis of the formulation. The results of this analysis confirm that the Nyacol Envirox formulation does not match the compostion statement issued to Neuftec by Oxonica. Neuftec Limited thus reserves its position regarding its rights to claim infringement in respect of all other formulations of Envirox supplied to other parties.

As reported earlier this month, the latest alleged infringement occurred when Oxonica shipped Envirox formulations to Italy for use in Italian Government laboratory emission testing. Neuftec is continuing it's investigations with customers, distributors & agents of Oxonica to determine the extent of the alleged infringement. Neuftec issued proceedings to seek an injunction against Oxonica as well as damages in relation to product already sold and delivery up or destruction of all articles that would infringe Neuftec's European patent.

About Neuftec

Neuftec is a research & development company that owns patents in the fuel catalyst technology sector used in the production of the first version of EnviroxTM (2001-2007) that was manufactured by Advanced Nanotechnology ("ANO") of Australia under a manufacturing licence granted by Oxonica with authorization from Neuftec.

On 29 February 2008, IP Australia issued a re-examination report in respect of Neuftec's Australian patent. The patent had been issued in 2006 with 10 claims. In the re-examination report, IP Australia confirmed the patentability of the 10 claims as originally granted in 2006 in re-examination proceedings initiated by Oxonica.

SOURCE Neuftec Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neuftec Issues Patent Infringement Proceedings in the UK Against Oxonica
2. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
3. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
4. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
5. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
6. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
7. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
8. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
9. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
10. MichBio Responds to Governors Plan to Repeal Tort Reform Laws
11. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):